← TagsCompany

Bio-Techne

2 articles

Germany's Merck raises 2026 guidance for third time

German drugmaker Merck KGaA raised its 2026 core profit guidance to €6.2-6.4 billion EBITDA, driven by strong Q3 performance and the Bio-Techne acquisition. The company highlighted growth in biomanufa

reuters · 2026-11-11 22:27